Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-
617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical …

The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

With a short particle range and high linear energy transfer, α-emitting radionuclides
demonstrate high cell-killing efficiencies. Even with the existence of numerous radionuclides …

Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer …

The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to
cancer cells while minimizing systemic toxic effects and may lead to additional treatment …

PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant
prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface …